Payment overview · 2025
General Payments
$1,440.58
63 reported records · 23 companies
Healthcare provider profile · identity verified
Christopher R Andrew, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · JOPLIN, MO · NPI 1184660995
Verified facts
What the public records show
CMS Open Payments records show Christopher R Andrew, MD received $1,440.58 in general payments during 2025 across 63 reported records.
Eisai Inc. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C, Nurtec Odt, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Qulipta by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tecfidera by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Gamunex-C by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $295.12 | 20.5% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $216.44 | 15.0% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.97 | 14.1% | 7 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $133.27 | 9.2% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $83.77 | 5.8% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $55.12 | 3.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.33 | 2.9% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $40.98 | 2.8% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $34.17 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $33.49 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.10 | 2.2% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $31.63 | 2.2% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $29.61 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.05 | 2.0% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.00 | 2.0% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $24.46 | 1.7% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $24.09 | 1.7% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $19.13 | 1.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.08 | 1.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.93 | 1.2% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $17.27 | 1.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.15 | 1.1% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $14.42 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,425.88 | 62 |
| Education | $14.70 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $295.12 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $216.44 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $181.81 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $154.78 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $84.90 | 4 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $67.29 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $55.12 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $48.37 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $42.33 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $33.49 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.10 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.10 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $29.00 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 586 | 98 |
| Nortriptyline Hcl | Nortriptyline Hcl | 525 | 97 |
| Levetiracetam | Levetiracetam | 435 | 52 |
| Topiramate | Topiramate | 422 | 69 |
| Donepezil Hcl | Donepezil Hcl | 346 | 71 |
| Lamotrigine | Lamotrigine | 322 | 32 |
| Pregabalin | Pregabalin | 308 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 239 | 49 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 225 | 47 |
| Primidone | Primidone | 219 | 46 |
| Divalproex Sodium | Divalproex Sodium | 212 | 41 |
| Carbamazepine Er | Carbamazepine | 196 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 25 |
| Lacosamide | Lacosamide | 191 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 36 |
| Memantine Hcl | Memantine Hcl | 169 | 33 |
| Clonazepam | Clonazepam | 166 | 22 |
| Tramadol Hcl | Tramadol Hcl | 151 | 23 |
| Baclofen | Baclofen | 149 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 144 | 24 |
| Diazepam | Diazepam | 127 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 124 | 26 |
| Carbamazepine | Carbamazepine | 118 | 15 |
| Zonisamide | Zonisamide | 105 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 102 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 96 | 20 |
| Aimovig Autoinjector | Erenumab-Aooe | 95 | 12 |
| Aripiprazole | Aripiprazole | 95 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 90 | 22 |
| Buspirone Hcl | Buspirone Hcl | 85 | 12 |
| Sertraline Hcl | Sertraline Hcl | 82 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 79 | 17 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 77 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 76 | suppressed |
| Teriflunomide | Teriflunomide | 74 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 71 | 16 |
| Amantadine | Amantadine Hcl | 66 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 14 |
| Modafinil | Modafinil | 62 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 57 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 56 | suppressed |
| Alprazolam | Alprazolam | 55 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 55 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 54 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 50 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 49 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 16 |
| Qulipta | Atogepant | 46 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 38 | 11 |
| Carisoprodol | Carisoprodol | 36 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 36 | suppressed |
| Dalfampridine Er | Dalfampridine | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Prednisone | Prednisone | 34 | 11 |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 31 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 27 | suppressed |
| Glatopa | Glatiramer Acetate | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Armodafinil | Armodafinil | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 22 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 16 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 16 | suppressed |
| Levetiracetam Er | Levetiracetam | 16 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 14 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Fingolimod | Fingolimod Hcl | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Copaxone | Glatiramer Acetate | 11 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 11 | suppressed |
| Tecfidera | Dimethyl Fumarate | 11 | suppressed |
| Tegretol | Carbamazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,440.58 · 63 records | Eisai Inc. | AUSTEDO XR, BOTOX, Bimzelx, DAYBUE, EPIDIOLEX, Gamunex-C, HYQVIA, Hizentra, KESIMPTA, LUPKYNIS, Leqembi, NURTEC ODT, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, QUTENZA, REXULTI, Rystiggo, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, VUMERITY, VYALEV, VYEPTI, ZAVZPRET, ZEPOSIA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error